Viatris Research and Development Expenses 2010-2024 | VTRS
Viatris annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
- Viatris research and development expenses for the quarter ending September 30, 2024 were $0.198B, a 6.06% decline year-over-year.
- Viatris research and development expenses for the twelve months ending September 30, 2024 were $805M, a 2.57% increase year-over-year.
- Viatris annual research and development expenses for 2023 were $0.805B, a 21.59% increase from 2022.
- Viatris annual research and development expenses for 2022 were $0.662B, a 2.76% decline from 2021.
- Viatris annual research and development expenses for 2021 were $0.681B, a 32.85% increase from 2020.
| Viatris Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2023 | $805 |
| 2022 | $662 |
| 2021 | $681 |
| 2020 | $513 |
| 2019 | $640 |
| 2018 | $705 |
| 2017 | $783 |
| 2016 | $827 |
| 2015 | $672 |
| 2014 | $582 |
| 2013 | $508 |
| 2012 | $401 |
| 2011 | $295 |
| 2010 | $282 |
| 2009 | $275 |
| Viatris Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2024-09-30 | $198 |
| 2024-06-30 | $204 |
| 2024-03-31 | $200 |
| 2023-12-31 | $203 |
| 2023-09-30 | $211 |
| 2023-06-30 | $208 |
| 2023-03-31 | $183 |
| 2022-12-31 | $182 |
| 2022-09-30 | $175 |
| 2022-06-30 | $163 |
| 2022-03-31 | $142 |
| 2021-12-31 | $197 |
| 2021-09-30 | $152 |
| 2021-06-30 | $148 |
| 2021-03-31 | $184 |
| 2020-12-31 | $112 |
| 2020-09-30 | $130 |
| 2020-06-30 | $156 |
| 2020-03-31 | $114 |
| 2019-12-31 | $152 |
| 2019-09-30 | $168 |
| 2019-06-30 | $148 |
| 2019-03-31 | $173 |
| 2018-12-31 | $149 |
| 2018-09-30 | $144 |
| 2018-06-30 | $207 |
| 2018-03-31 | $205 |
| 2017-12-31 | $202 |
| 2017-09-30 | $182 |
| 2017-06-30 | $181 |
| 2017-03-31 | $218 |
| 2016-12-31 | $195 |
| 2016-09-30 | $199 |
| 2016-06-30 | $180 |
| 2016-03-31 | $254 |
| 2015-12-31 | $159 |
| 2015-09-30 | $175 |
| 2015-06-30 | $168 |
| 2015-03-31 | $170 |
| 2014-12-31 | $150 |
| 2014-09-30 | $158 |
| 2014-06-30 | $155 |
| 2014-03-31 | $118 |
| 2013-12-31 | $156 |
| 2013-09-30 | $114 |
| 2013-06-30 | $111 |
| 2013-03-31 | $127 |
| 2012-12-31 | $118 |
| 2012-09-30 | $108 |
| 2012-06-30 | $94 |
| 2012-03-31 | $81 |
| 2011-12-31 | $76 |
| 2011-09-30 | $71 |
| 2011-06-30 | $72 |
| 2011-03-31 | $75 |
| 2010-12-31 | $82 |
| 2010-09-30 | $72 |
| 2010-06-30 | $67 |
| 2010-03-31 | $61 |
| 2009-12-31 | $73 |
| 2009-09-30 | $70 |
| 2009-06-30 | $74 |
| 2009-03-31 | $59 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $15.576B | $15.427B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $91.424B | 11.34 |
| Cencora (COR) | United States | $47.484B | 17.51 |
| DiDi Global (DIDIY) | China | $23.330B | 0.00 |
| Natera (NTRA) | United States | $21.401B | 0.00 |
| ICON (ICLR) | Ireland | $16.136B | 14.37 |
| Avantor (AVTR) | United States | $13.422B | 20.12 |
| Revvity (RVTY) | United States | $13.376B | 23.24 |
| CochLear (CHEOY) | Australia | $12.844B | 0.00 |
| BioMerieux (BMXMF) | France | $12.666B | 0.00 |
| Solventum (SOLV) | United States | $11.583B | 0.00 |
| Medpace Holdings (MEDP) | United States | $9.789B | 27.58 |
| Doximity (DOCS) | United States | $9.620B | 56.63 |
| Charles River Laboratories (CRL) | United States | $9.516B | 18.39 |
| HealthEquity (HQY) | United States | $8.966B | 48.66 |
| Sonic Healthcare (SKHHY) | Australia | $8.758B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.885B | 32.05 |
| Life Times (LTH) | United States | $5.085B | 33.66 |
| Sotera Health (SHC) | United States | $3.855B | 20.62 |
| Organon (OGN) | United States | $3.757B | 3.79 |
| BrightSpring Health Services (BTSG) | United States | $3.247B | 69.07 |
| Surgery Partners (SGRY) | United States | $2.892B | 32.97 |
| PACS (PACS) | United States | $2.606B | 0.00 |
| Concentras Parent (CON) | United States | $2.581B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.375B | 0.00 |
| Premier (PINC) | United States | $2.143B | 11.15 |
| Alignment Healthcare (ALHC) | United States | $2.126B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $2.036B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.952B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.616B | 42.40 |
| Teladoc Health (TDOC) | United States | $1.537B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.255B | 12.28 |
| CareDx (CDNA) | United States | $1.183B | 0.00 |
| Progyny (PGNY) | United States | $1.164B | 23.57 |
| Establishment Labs Holdings (ESTA) | $1.050B | 0.00 | |
| AMN Healthcare Services Inc (AMN) | United States | $0.954B | 6.46 |
| QDM (QDMI) | Hong Kong, SAR China | $0.790B | 20.69 |
| Embecta (EMBC) | United States | $0.778B | 5.18 |
| SBC Medicals (SBC) | United States | $0.677B | 0.00 |
| Agilon Health (AGL) | United States | $0.655B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.647B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.536B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.425B | 0.00 |
| DocGo (DCGO) | United States | $0.410B | 15.46 |
| Enhabit (EHAB) | United States | $0.366B | 31.61 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.326B | 0.00 |
| LifeMD (LFMD) | United States | $0.241B | 0.00 |
| ModivCare (MODV) | United States | $0.223B | 12.09 |
| Sera Prognostics (SERA) | United States | $0.209B | 0.00 |
| Beauty Health (SKIN) | United States | $0.200B | 0.00 |
| Biodesix (BDSX) | United States | $0.180B | 0.00 |
| Nutex Health (NUTX) | United States | $0.156B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.100B | 0.00 |
| So-Young (SY) | China | $0.092B | 22.25 |
| MultiPlan (MPLN) | United States | $0.084B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.054B | 0.00 |
| OncoCyte (OCX) | United States | $0.043B | 0.00 |
| NeueHealth (NEUE) | United States | $0.041B | 1.08 |
| Co-Diagnostics (CODX) | United States | $0.034B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.030B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.028B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.020B | 0.00 |
| Oncology Institute (TOI) | United States | $0.014B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| KindlyMD (KDLY) | United States | $0.005B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |